Financing ·
Dogwood Therapeutics prices $5M private placement of common stock at $1.22 per share
DWTXDogwood Therapeutics, Inc.
Dogwood Therapeutics entered into a subscription agreement to issue and sell 4,098,360 shares of common stock in a private placement to Sealbond Limited, an affiliate of largest shareholder CK Life Sciences Int’l., (Holdings) Inc. The shares were sold at $1.22 per share, generating approximately $5 million in gross proceeds before offering expenses. The transaction is expected to close on or prior to October 29, 2026. Dogwood intends to use the net proceeds for Phase 3 preparatory activities for its lead drug candidate Halneuron®, as well as general working capital and corporate purposes. This investment extends the company's operational runway through March 2027. Dogwood Therapeutics is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders.